Hyper
What about reimbursement? Oncosil briefly mentions that they are looking into this issue. Isn’t reimbursement the key? What’s your take on this?
Cheers
GW
Ann: OncoSil FY21 half yearly review, page-9
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $31.31M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.7¢ | $19.71K | 2.475M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 25681033 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 5068750 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| OSL (ASX) Chart |